Predictive Oncology Inc.Predictive Oncology Inc.Predictive Oncology Inc.

Predictive Oncology Inc.

No trades
See on Supercharts
Market capitalization
‪7.15 M‬USD
−3.48USD
‪−13.98 M‬USD
‪1.78 M‬USD
‪3.94 M‬
Beta (1Y)
2.61

About Predictive Oncology Inc.

CEO
Raymond F. Vennare
Headquarters
Pittsburgh
Employees (FY)
34
Founded
2002
ISIN
US74039M3097
FIGI
BBG000PVXTF7
Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes contract services that include the application of AI, partnering projects, and clinical testing. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment is composed of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within the Corporate segment. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Pittsburgh, PA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of POAI is 1.76 USD — it has decreased by 1.12% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Predictive Oncology Inc. stocks are traded under the ticker POAI.
Predictive Oncology Inc. is going to release the next earnings report on May 14, 2024. Keep track of upcoming events with our Earnings Calendar.
POAI earnings for the last quarter are −1.00 USD whereas the estimation was −0.20 USD which accounts for −400.00% surprise. Estimated earnings for the next quarter are −1.20 USD. See more details about Predictive Oncology Inc. earnings.
Predictive Oncology Inc. revenue for the last quarter amounts to ‪455.83 K‬ USD despite the estimated figure of ‪4.00 M‬ USD. In the next quarter revenue is expected to reach ‪500.00 K‬ USD.
Yes, you can track Predictive Oncology Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, POAI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Predictive Oncology Inc. stock right from TradingView charts — choose your broker and connect to your account.
POAI reached its all-time high on Aug 27, 2013 with the price of 176691.80 USD, and its all-time low was 1.68 USD and was reached on Apr 10, 2024.
See other stocks reaching their highest and lowest prices.
As of Apr 14, 2024, the company has 34.00 employees. See our rating of the largest employees — is Predictive Oncology Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Predictive Oncology Inc. EBITDA is ‪−13.18 M‬ USD, and current EBITDA margin is −740.52%. See more stats in Predictive Oncology Inc. financial statements.